Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 | Contract Pharma

What are you searching for?

Sign in

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co. received approval from the FDA for Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder. Cymbalta is the first serotonin-norepinephrine reuptake inhibitor that has shown efficacy in reducing pain in patients with fibromyalgia. Cymbalta is also approved for the management of diabetic peripheral neuropathic pain (DPNP), the treatment of major depressive disorder, and generalized anxiety disorder.

“The approval of Cymbalta is important because it provides physicians and patients with a new treatment option shown to help reduce pain and improve functioning in this difficult-to-treat disorder,” said Madelaine Wohlreich, M.D., medical advisor and research physician at Lilly.

 

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters